Literature DB >> 29691293

Immunotherapy for Glioblastoma: Playing Chess, Not Checkers.

Christopher M Jackson1, Michael Lim2.   

Abstract

Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression and tolerance. These pathways are now being identified and their relative contributions explored. Delineating how these pathways are interrelated is paramount to effectively implementing immunotherapy for GBM. Clin Cancer Res; 24(17); 4059-61. ©2018 AACRSee related articles by Woroniecka et al., p. 4175 and Mohme et al., p. 4187. ©2018 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2018        PMID： 29691293     DOI： 10.1158/1078-0432.CCR-18-0491

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).

Authors:  Vassilis Genoud; Felipe I Espinoza; Eliana Marinari; Viviane Rochemont; Pierre-Yves Dietrich; Paul McSheehy; Felix Bachmann; Heidi A Lane; Paul R Walker
Journal:  JCI Insight       Date:  2021-09-22

2.  An Immune-Related Gene Pairs Signature Predicts Prognosis and Immune Heterogeneity in Glioblastoma.

Authors:  Nijia Zhang; Ming Ge; Tao Jiang; Xiaoxia Peng; Hailang Sun; Xiang Qi; Zhewei Zou; Dapeng Li
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

3.  Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.

Authors:  Kaidi Yang; Yu Shi; Min Luo; Min Mao; Xiaoning Zhang; Cong Chen; Yuqi Liu; Zhicheng He; Qing Liu; Wenying Wang; Chunhua Luo; Wen Yin; Chao Wang; Qin Niu; Hui Zeng; Xiu-Wu Bian; Yi-Fang Ping
Journal:  Oncoimmunology       Date:  2022-01-26       Impact factor: 8.110

4.  An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas.

Authors:  Gang Xiao; Xuan Gao; Lifeng Li; Chao Liu; Zhiyuan Liu; Haiqin Peng; Xuefeng Xia; Xin Yi; Rongrong Zhou
Journal:  J Oncol       Date:  2021-12-18       Impact factor: 4.375

5.  Network pharmacology-based screening of the active ingredients and mechanisms of evodiae fructus anti-glioblastoma multiforme.

Authors:  Gang Wu; Qingpei Hao; Bo Liu; Jingru Zhou; Cungang Fan; Ruen Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

6.  Treatment Combining CD200 Immune Checkpoint Inhibitor and Tumor-Lysate Vaccination after Surgery for Pet Dogs with High-Grade Glioma.

Authors:  Michael R Olin; Elisabet Ampudia-Mesias; Christopher A Pennell; Aaron Sarver; Clark C Chen; Christopher L Moertel; Matthew A Hunt; G Elizabeth Pluhar
Journal:  Cancers (Basel)       Date:  2019-01-24       Impact factor: 6.639

7.  Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography.

Authors:  Darpan N Pandya; Akesh Sinha; Hong Yuan; Lysette Mutkus; Kristina Stumpf; Frank C Marini; Thaddeus J Wadas
Journal:  Molecules       Date:  2020-08-12       Impact factor: 4.411

8.  CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.

Authors:  Ayaka Hara; Ryo Koyama-Nasu; Mariko Takami; Takahide Toyoda; Takahiro Aoki; Fumie Ihara; Masayoshi Kobayashi; Seiichiro Hirono; Tomoo Matsutani; Toshinori Nakayama; Yasuo Iwadate; Shinichiro Motohashi
Journal:  Cancer Immunol Immunother       Date:  2020-10-31       Impact factor: 6.968
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.